Achieve Life Sciences (ACHV) vs Avalo Therapeutics (AVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 118.1% versus a gain of 0.7%. Over five years, ACHV leads with a -10.1% price change compared with -99.8% for AVTX. Achieve Life Sciences is the larger company by market cap ($731.0 million vs $687.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | AVTX |
|---|---|---|
| Share price | $7.09 | $12.81 |
| Market cap | $731.00M | $687.00M |
| 1-day change | -2.07% | -5.67% |
| YTD return | +45.67% | -25.22% |
| 1-year return | +118.07% | +0.74% |
| 5-year return | -10.06% | -99.79% |
| EPS (TTM) | $-1.69 | $-4.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $24.27 |
| 52-week low | $2.62 | $12.51 |
| Distance from 52-week high | -17.94% | -47.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.58% | +244.11% |
| Average volume | 1.44M | 926.15K |
| Shares outstanding | 103.10M | 53.63M |
| Employees | 28 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed AVTX by 117.3 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
ACHV vs AVTX FAQ
Which is bigger, Achieve Life Sciences or Avalo Therapeutics?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $731.00M compared with $687.00M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, ACHV or AVTX?
ACHV returned +118.07% over the past 12 months, compared with +0.74% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Avalo Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Achieve Life Sciences and Biotechnology: Pharmaceutical Preparations for Avalo Therapeutics.